Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 6
2013 5
2014 4
2015 12
2016 26
2017 23
2018 32
2019 47
2020 62
2021 38
2022 39
2023 44
2024 36
2025 43
2026 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

378 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group. Baeten D, et al. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066. N Engl J Med. 2015. PMID: 26699169 Free article. Clinical Trial.
BACKGROUND: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials of secukinumab in patients with active ankylosing …
BACKGROUND: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing …
Secukinumab: A Review in Ankylosing Spondylitis.
Blair HA. Blair HA. Drugs. 2019 Mar;79(4):433-443. doi: 10.1007/s40265-019-01075-3. Drugs. 2019. PMID: 30793255 Free PMC article. Review.
Secukinumab (Cosentyx( )), a first-in-class fully human monoclonal antibody against interleukin-17A, is approved in several countries, including the USA and those of the EU, for the treatment of ankylosing spondylitis (AS). ...In MEASURE 1, secukinumab …
Secukinumab (Cosentyx( )), a first-in-class fully human monoclonal antibody against interleukin-17A, is approved in several countries …
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Gottlieb AB, Deodhar A, Mcinnes IB, Baraliakos X, Reich K, Schreiber S, Bao W, Marfo K, Richards HB, Pricop L, Shete A, Trivedi V, Keefe D, Papavassilis CC, Jagiello P, Papanastasiou P, Mease PJ, Lebwohl M. Gottlieb AB, et al. Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563. Acta Derm Venereol. 2022. PMID: 35146532 Free PMC article.
Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and paediatric psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. ...Analyses included 12,637 secukinumab-treated pa …
Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and paediatric psoriasis, psoriatic arthritis, …
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. Ward MM, et al. Arthritis Care Res (Hoboken). 2019 Oct;71(10):1285-1299. doi: 10.1002/acr.24025. Epub 2019 Aug 21. Arthritis Care Res (Hoboken). 2019. PMID: 31436026 Free PMC article. Review.
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). METHODS: We conducted updated systematic literature reviews for 20 clinical questions on pharmacolog …
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradi …
Safety of secukinumab for the treatment of active ankylosing spondylitis.
Loricera J, Galíndez-Aguirregoikoa E, Blanco R. Loricera J, et al. Expert Opin Drug Saf. 2021 Jun;20(6):627-634. doi: 10.1080/14740338.2021.1851363. Epub 2021 Jan 20. Expert Opin Drug Saf. 2021. PMID: 33470130 Review.
Introduction: Secukinumab is a fully human monoclonal antibody which targets and neutralizes interleukin (IL)-17A, a cytokine that plays an important role in the pathophysiology of ankylosing spondylitis (AS). Secukinumab is the first IL-17A inhibitor …
Introduction: Secukinumab is a fully human monoclonal antibody which targets and neutralizes interleukin (IL)-17A, a cytokine that pl …
Secukinumab: A Review in Ankylosing Spondylitis.
Blair HA, Dhillon S. Blair HA, et al. Drugs. 2016 Jul;76(10):1023-30. doi: 10.1007/s40265-016-0598-8. Drugs. 2016. PMID: 27255593 Review.
Secukinumab (Cosentyx( )) is a fully human monoclonal antibody against the proinflammatory cytokine interleukin-17A. It is the first drug in its class to be approved for use in patients with active ankylosing spondylitis (AS). This article reviews the efficac …
Secukinumab (Cosentyx( )) is a fully human monoclonal antibody against the proinflammatory cytokine interleukin-17A. It is the first …
Secukinumab (AIN457) in the treatment of ankylosing spondylitis.
Braun J, Baraliakos X, Kiltz U. Braun J, et al. Expert Opin Biol Ther. 2016;16(5):711-22. doi: 10.1517/14712598.2016.1167183. Expert Opin Biol Ther. 2016. PMID: 26982813 Review.
INTRODUCTION: Ankylosing spondylitis (AS) is a chronic immune-mediated disease characterised by inflammation and new bone formation in the axial skeleton. ...Here we provide an overview of the pharmacology, clinical efficacy and safety of secukinumab in the t …
INTRODUCTION: Ankylosing spondylitis (AS) is a chronic immune-mediated disease characterised by inflammation and new bone form …
Secukinumab for ankylosing spondylitis and psoriatic arthritis.
Lubrano E, Perrotta FM. Lubrano E, et al. Ther Clin Risk Manag. 2016 Oct 21;12:1587-1592. doi: 10.2147/TCRM.S100091. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 27799780 Free PMC article. Review.
The treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) positively changed since the introduction of anti-TNFalpha drugs. ...The aim of this article was to review the pathophysiological basis, the efficacy and the safety of secukinumab trea …
The treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) positively changed since the introduction of anti-T …
Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis.
Katsevman GA, Mariscal G, Barrios C, Domenech-Fernández P, Ziembinski C, Bhatia S. Katsevman GA, et al. Monoclon Antib Immunodiagn Immunother. 2020 Oct;39(5):160-166. doi: 10.1089/mab.2020.0022. Epub 2020 Oct 1. Monoclon Antib Immunodiagn Immunother. 2020. PMID: 33001775 Free PMC article.
The aim of this study was to compare the efficacy and safety of secukinumab in ankylosing spondylitis. A systematic review was conducted using MEDLINE and EMBASE databases to identify randomized clinical trials (RCTs) that assess the role of secukinumab …
The aim of this study was to compare the efficacy and safety of secukinumab in ankylosing spondylitis. A systematic rev …
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. Ward MM, et al. Arthritis Rheumatol. 2019 Oct;71(10):1599-1613. doi: 10.1002/art.41042. Epub 2019 Aug 22. Arthritis Rheumatol. 2019. PMID: 31436036 Free PMC article.
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). METHODS: We conducted updated systematic literature reviews for 20 clinical questions on pharmacolog …
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradi …
378 results